Aarti Pharmalabs reported a mixed set of Q4 FY26 earnings, with revenue witnessing marginal growth while profitability and operating margins declined on a year-on-year basis.
The company posted a net profit of ₹56.3 crore in the fourth quarter, down 33% compared to ₹83.6 crore reported in the corresponding quarter last year.
Revenue from operations increased 3.3% year-on-year to ₹582.6 crore against ₹563.8 crore reported in the same period of the previous fiscal.
On the operational front, EBITDA declined 21% to ₹113.2 crore from ₹143.2 crore in Q4 FY25. EBITDA margin also contracted sharply to 19.4% compared to 25.4% in the year-ago quarter.
The decline in margins and profitability indicates pressure on operating performance despite stable revenue growth during the quarter. Market participants are expected to monitor the company’s outlook on demand trends, cost pressures, and margin recovery going ahead.
Following the earnings announcement, the stock came under selling pressure in Tuesday’s trading session. As of 1:33 PM IST, Aarti Pharmalabs shares were trading 4.80% lower at ₹697.30.
The stock touched an intraday low of ₹691.25 and a high of ₹720.00 during the session. The opening price stood at ₹706.80, while the previous close was ₹732.45. The counter witnessed a live trading volume of 3.84 lakh shares.
Over the past 52 weeks, the stock has touched a high of ₹971.00 and a low of ₹585.00.